AYTU BIOPHARMA, INC Increase (Decrease) in Other Operating Assets and Liabilities, Net
AYTU BIOPHARMA, INC (AYTU) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of -$696.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-09-22
- AYTU BIOPHARMA, INC increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-06-30 was $54.00K.
- AYTU BIOPHARMA, INC increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-03-31 was -$165.00K.
- AYTU BIOPHARMA, INC increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-12-31 was -$182.00K.
- AYTU BIOPHARMA, INC increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-09-30 was -$403.00K.
- AYTU BIOPHARMA, INC increase (decrease) in other operating assets and liabilities, net for fiscal 2026 was -$696.00K.
- AYTU BIOPHARMA, INC increase (decrease) in other operating assets and liabilities, net for fiscal 2025 was -$528.00K.
- AYTU BIOPHARMA, INC increase (decrease) in other operating assets and liabilities, net for fiscal 2024 was -$3.80M, a 303.04% decline from fiscal 2023.
- AYTU BIOPHARMA, INC increase (decrease) in other operating assets and liabilities, net for fiscal 2023 was $1.87M.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month as first filed | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month as first filed | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | -$111.00K derived: sum of 2 quarters · filed 2026-09-22 | -$293.00K derived: sum of 3 quarters · filed 2026-09-22 | -$696.00K 10-K · filed 2026-09-22 | |||
| 2026-03-31 | -$165.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | -$347.00K derived: sum of 2 quarters · filed 2026-05-13 | -$750.00K 10-Q · filed 2026-05-13 | -$923.00K derived: sum of 4 quarters · filed 2026-09-22 | |||
| 2025-12-31 | -$182.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | -$585.00K 10-Q · filed 2026-02-03 | -$758.00K derived: sum of 3 quarters · filed 2026-09-22 | -$807.00K derived: sum of 4 quarters · filed 2026-09-22 | |||
| 2025-09-30 | -$403.00K 10-Q · filed 2025-11-13 | -$576.00K derived: sum of 2 quarters · filed 2026-09-22 | -$625.00K derived: sum of 3 quarters · filed 2026-09-22 | -$830.00K derived: sum of 4 quarters · filed 2026-09-22 | |||
| 2025-06-30 | -$173.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | -$222.00K derived: sum of 2 quarters · filed 2026-09-22 | -$427.00K derived: sum of 3 quarters · filed 2026-09-22 | -$528.00K 10-K · filed 2026-09-22 | |||
| 2025-03-31 | -$49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | -$254.00K derived: sum of 2 quarters · filed 2026-05-13 | -$355.00K 10-Q · filed 2026-05-13 | -$310.00K derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | -$205.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | -$306.00K 10-Q · filed 2026-02-03 | -$261.00K derived: sum of 3 quarters · filed 2026-02-03 | -$302.00K derived: sum of 4 quarters · filed 2026-02-03 | |||
| 2024-09-30 | -$101.00K 10-Q · filed 2025-11-13 | -$56.00K derived: sum of 2 quarters · filed 2025-11-13 | -$101.00K 10-Q · filed 2024-11-13 | -$158.00K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $4.00K derived: sum of 2 quarters · filed 2025-09-23 | -$57.00K derived: sum of 3 quarters · filed 2025-09-23 | -$3.80M 10-K · filed 2025-09-23 | -$3.85M 10-K · filed 2024-09-26 | ||
| 2024-03-31 | -$41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | -$102.00K derived: sum of 2 quarters · filed 2025-05-14 | -$3.85M 10-Q · filed 2025-05-14 | -$3.89M 10-Q · filed 2024-05-15 | -$2.06M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | -$3.81M 10-Q · filed 2025-02-12 | -$3.85M 10-Q · filed 2024-02-14 | -$2.02M derived: sum of 3 quarters · filed 2025-02-12 | -$2.01M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-09-30 | -$3.74M 10-Q · filed 2023-11-14 | -$1.96M derived: sum of 2 quarters · filed 2024-09-26 | -$3.74M 10-Q · filed 2024-11-13 | -$1.94M derived: sum of 4 quarters · filed 2024-09-26 | |||
| 2023-06-30 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $1.80M derived: sum of 2 quarters · filed 2024-09-26 | $1.80M derived: sum of 3 quarters · filed 2024-09-26 | $1.87M 10-K · filed 2024-09-26 | $111.00K 10-K · filed 2023-10-12 | ||
| 2023-03-31 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $11.00K derived: sum of 2 quarters · filed 2024-05-15 | $83.00K 10-Q · filed 2024-05-15 | $85.00K derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $76.00K 10-Q · filed 2024-02-14 | $78.00K derived: sum of 3 quarters · filed 2024-02-14 | $77.00K derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2022-09-30 | $72.00K 10-Q · filed 2023-11-14 | $74.00K derived: sum of 2 quarters · filed 2023-11-14 | $73.00K derived: sum of 3 quarters · filed 2023-11-14 | $169.00K derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $1.00K derived: sum of 2 quarters · filed 2023-10-12 | $97.00K derived: sum of 3 quarters · filed 2023-10-12 | -$50.00K 10-K · filed 2023-10-12 | |||
| 2022-03-31 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | $95.00K derived: sum of 2 quarters · filed 2023-05-11 | -$52.00K 10-Q · filed 2023-05-11 | $253.00K derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $96.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-02-21 | -$51.00K 10-Q · filed 2023-02-21 | $254.00K derived: sum of 3 quarters · filed 2023-02-21 | $257.00K derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2021-09-30 | -$147.00K 10-Q/A · filed 2023-02-21 | $158.00K derived: sum of 2 quarters · filed 2023-02-21 | $161.00K derived: sum of 3 quarters · filed 2023-02-21 | $158.00K derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2021-06-30 | $305.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $308.00K derived: sum of 2 quarters · filed 2022-09-27 | $305.00K derived: sum of 3 quarters · filed 2022-09-27 | $332.00K 10-K · filed 2022-09-27 | |||
| 2021-03-31 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2022-05-16 | $27.00K 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $24.00K 10-Q · filed 2022-02-14 | |||||
| 2020-09-30 | $27.00K 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | $0.00 10-K · filed 2021-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |